Sensitization of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery
Abstract
In the third year of this three-year project, we have completed most of the tasks following the timeline of our Statement of Work. Although the COVID-19 pandemic has severely affected progress of the project during this year by interrupting some of the proposed studies, we are excited to report our studies performed confirms that HMCD-SIM demonstrates cytotoxic activity in pancreatic cancer cells in vitro and furthermore demonstrates tumor growth inhibition in pancreatic cancer xenografts. These experimental data obtained strongly support our main hypothesis that HMCD-SIM is a potential potent new anti-tumor agent drug for pancreatic cancer. This was our main goal of our third year of experimentation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1155711
Entities
People
- James S. Tomlinson
- Leland W. Chung
- Stephen J Pandol
Organizations
- University of California, Los Angeles